ADVERTISEMENT
Chitwood & Harley, LLP, a class action law firm with a national practice, is investigating bringing a class action against Bradley Pharmaceuticals, Inc. ("Bradley") for violations of the the federal securities laws. The firm is interested in interviewing anyone who lost money on the Bradley Pharmaceutical securities as a result of the Company's disclosure of the informal inquiry by the Securities and Exchange Commission (the "SEC"). The firm is in the process of evaluating if there was fraud on the market prior to the announcement of the SEC's inquiry and, if so, for what period of time that fraud on the market occurred.
Before the market opened on Feb. 28, 2005, Bradley issued a press release announcing that the SEC is conducting an informal inquiry relating to the Company to determine whether there have been violations of the federal securities laws. In connection with the inquiry, the press release said, the SEC staff has requested that the Company provide it with certain information and documents, including with respect to revenue recognition and capitalization of certain payments.
Bradley has admitted that it first received notice of the SEC's informal inquiry in December. In late February, it received a second letter from the SEC. The inquiry, however, was not disclosed until February 28, 2005.
If you have suffered a loss on your Bradley securities as a result of Bradley's February 28, 2005 disclosure, you may have a claim under the Securities Exchange Act of 1934. If you would like to hear from an attorney to discuss whether you have a claim and what your options are, please fill in our form on the right to submit your complaint. You may also contact Lauren S. Antonino, Esq. at lsa@classlaw.com or 1-888-873-3999 ext 6888 to discuss your options.
Chitwood & Harley, LLP, a class action law firm with a national practice, is investigating bringing a class action against Bradley Pharmaceuticals, Inc. ("Bradley") for violations of the the federal securities laws. The firm is interested in interviewing anyone who lost money on the Bradley Pharmaceutical securities as a result of the Company's disclosure of the informal inquiry by the Securities and Exchange Commission (the "SEC"). The firm is in the process of evaluating if there was fraud on the market prior to the announcement of the SEC's inquiry and, if so, for what period of time that fraud on the market occurred.
Before the market opened on Feb. 28, 2005, Bradley issued a press release announcing that the SEC is conducting an informal inquiry relating to the Company to determine whether there have been violations of the federal securities laws. In connection with the inquiry, the press release said, the SEC staff has requested that the Company provide it with certain information and documents, including with respect to revenue recognition and capitalization of certain payments.
Bradley has admitted that it first received notice of the SEC's informal inquiry in December. In late February, it received a second letter from the SEC. The inquiry, however, was not disclosed until February 28, 2005.
If you have suffered a loss on your Bradley securities as a result of Bradley's February 28, 2005 disclosure, you may have a claim under the Securities Exchange Act of 1934. If you would like to hear from an attorney to discuss whether you have a claim and what your options are, please fill in our form on the right to submit your complaint. You may also contact Lauren S. Antonino, Esq. at lsa@classlaw.com or 1-888-873-3999 ext 6888 to discuss your options.
